Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Core Viewpoint - Rocket Pharmaceuticals has withdrawn its application for U.S. approval of its experimental gene therapy targeting a rare inherited blood disorder [1] Company Summary - The decision to withdraw the application indicates potential challenges in the approval process for the gene therapy [1] - This move may impact the company's future development plans and financial outlook related to this therapy [1] Industry Summary - The withdrawal reflects broader challenges faced by companies in the gene therapy sector, particularly in obtaining regulatory approvals for innovative treatments [1] - The incident may influence investor sentiment and market dynamics within the biotechnology industry, especially for firms focused on rare diseases [1]